Shares of Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) saw strong trading volume on Thursday . 1,068,768 shares were traded during mid-day trading, an increase of 154% from the previous session’s volume of 420,289 shares.The stock last traded at $2.45 and had previously closed at $2.15.
A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of Asterias Biotherapeutics in a report on Wednesday, November 22nd. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $9.19.
The stock has a market cap of $121.84, a PE ratio of -3.77 and a beta of 1.31.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.